Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial
2017 ◽
Vol 18
(6)
◽
pp. 732-742
◽
Keyword(s):
Phase 3
◽
2018 ◽
Vol 48
(9)
◽
pp. 855-859
◽
Keyword(s):